Monday, November 9, 2026

USD/EUR Over 2% Down In The Last 21 Sessions

USD/EUR Over 2% Down In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 2.27% for the last 21 sessions. At 20:12 EST on Tuesday, 27 June, USD/EUR (USDEUR) is $0.91.

USD/EUR's yearly highs and lows, it's 1.209% up from its 52-week low and 12.965% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a positive 0.02%, a negative 0.10%, and a positive 0.35%, respectively.

USD/EUR's highest amplitude of average volatility was 0.38% (last week), 0.33% (last month), and 0.35% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be oversold (<=20).

News about

  • Usd/jpy remains confined in a narrow range below YTD peak, downside seems cushioned. According to FXStreet on Tuesday, 27 June, "The USD/JPY pair extends its sideways consolidative price move for the second successive day on Tuesday and oscillates in a narrow band through the Asian session. ", "In the meantime, Tuesday's US economic docket - featuring Durable Goods Orders, the Conference Board's Consumer Confidence Index, New Home Sales and Richmond Manufacturing Index - will be looked upon for some impetus around the USD/JPY pair."
  • Usd/jpy price analysis: mildly bid within immediate bullish channel around 143.50. According to FXStreet on Monday, 26 June, "It's worth noting that an upward-sloping support line from early May and the 200-SMA, respectively near 140.80 and 139.40 are the extra checks for the USD/JPY bears before taking control.", "However, an upward-sloping trend channel from the last Wednesday joins bullish MACD signals to keep the USD/JPY buyers hopeful."
  • According to FXStreet on Monday, 26 June, "Most economists polled by Reuters predict that the Bank of Japan (BoJ) will step in to halt the Yen's decline if the USD/JPY reaches 145.00. "
  • Usd/jpy pulls back from YTD peak, trades with modest losses below mid-143.00s. According to FXStreet on Monday, 26 June, "This, along with the Federal Reserve's (Fed) hawkish outlook, might hold back traders from placing aggressive bearish bets around the USD and help limit any meaningful corrective decline for the USD/JPY pair, at least for now. ", "The data might influence market expectations about the Fed's next policy move, which, in turn, will drive the USD demand and provide a fresh directional impetus to the USD/JPY pair. "
  • According to FXStreet on Monday, 26 June, "On the other hand, according to a Reuters' poll, the majority of the economists interviewed believe that the Bank of Japan (BoJ) will intervene to stop the Yen's fall if the USD/JPY reaches 145.00. "

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com